PC-SPES study decision
This article was originally published in The Tan Sheet
Executive Summary
NCCAM anticipates releasing a decision on future of PC-SPES research "toward the end of August," NIH center states June 14. Four studies were placed on hold after February recall of the dietary supplement, coupled with sole manufacturer BotanicLab's subsequent shutdown (1"The Tan Sheet" June 3, 2002, In Brief)...
You may also be interested in...
PC-SPES studies
NCCAM-funded PC-SPEStrials, on hold since BotanicLab recalled the supplement in February, will remain in limbo until at least July, NIH center says. NCCAM decision-makers currently are meeting with PC-SPES study "stakeholders," patients, researchers to determine course of action. Trial's investigators hope additional sources of PC-SPES will become available. Of the four trials, three were in vitro studies; research involving humans had not yet begun (1"The Tan Sheet" June 3, 2002, p. 5)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.